Show simple item record

dc.contributor.authorDunn, N
dc.contributor.authorFogdell-Hahn, A
dc.contributor.authorHillert, J
dc.contributor.authorSpelman, T
dc.date.accessioned2020-12-09T22:39:11Z
dc.date.available2020-12-09T22:39:11Z
dc.date.issued2020
dc.identifier.citationDunn, N., Fogdell-Hahn, A., Hillert, J. & Spelman, T. (2020). Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis.. Front Immunol, 11, pp.583560-. https://doi.org/10.3389/fimmu.2020.583560.
dc.identifier.issn1664-3224
dc.identifier.urihttp://hdl.handle.net/11343/253030
dc.description.abstractBackground: Neutralizing anti-drug antibodies (NAbs) to interferon beta (IFNβ) develop in up to 47% of multiple sclerosis (MS) treated patients inhibiting treatment effect of IFNβ. However, the long-term effect of NAbs remain unknown. Objective: To investigate the long-term consequences of high titer NAbs to IFNβ on disease activity and progression in MS patients. Methods: An observational study including data from all IFNβ treated relapsing remitting MS patients with sufficient NAb test results from the Swedish MS registry. Patients were classified into either confirmed 'high titer' or 'persistent negative' groups and analyzed for differences in disease activity and progression over time. Results: A total of 197 high-titer and 2907 persistent negative patients with 19969.6 follow up years of data were included. High titer NAbs were associated with a higher degree of disease activity at baseline. However, even when accounting for this, the presence of high titer NAbs were also associated with higher disease activity during IFNβ treatment. This persisted even after the next DMT start, suggesting that earlier high titers may partially reduce the effect of later treatments. No difference was found in confirmed disability progression. Conclusion: High titer NAbs to IFNβ are associated with higher disease activity, persisting even after IFNβ discontinuation or switch. These results support use of highly efficient treatment earlier in patients with active disease, to avoid these complications.
dc.languageeng
dc.publisherFrontiers Media SA
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleLong-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis.
dc.typeJournal Article
dc.identifier.doi10.3389/fimmu.2020.583560
melbourne.affiliation.departmentSurgery (St Vincent's)
melbourne.source.titleFrontiers in Immunology
melbourne.source.volume11
melbourne.source.pages583560-
dc.rights.licenseCC BY
melbourne.elementsid1480514
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593513
melbourne.contributor.authorSpelman, Timothy
dc.identifier.eissn1664-3224
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record